Takeda in more trouble at home over recall of mislabeled vials

Drugmaker loses seat as head of regional GMP committee
Tools

Japan's Takeda has gotten into more local hot water over the recall earlier this year of a lot of its Alinamin-F5 dietary supplement sold in Japan for vitamin B1 deficiency. The Osaka Pharmaceutical Manufacturers Association (OPMA) has suspended Takeda's activities as chair of the good manufacturing practice (GMP) committee, and vice-chair of the pharmaceutical laws and regulations committee for 6 months starting March 29 because of the incident, Pharmafile reports. In February, Takeda's contract manufacturer Nihon Pharmaceutical was ordered by the Osaka Prefectural Government to close down for 12 days after a box of vials were found in the market without labels. The company determined that a box containing samples was being used to determine the correct placement of the label on the outer box but "was mistakenly put into the actual manufacturing line of the real product." Takeda said it took the OPMA action very seriously and had instituted new procedures to make sure the same mistake was not made again. Story | More

Filed Under